Assessment of the Risk of Inhibitor Formation in Subjects With Severe Hemophilia A When Switched From a Replacement Therapy With a rFVIII Produced by a Chinese Hamster Ovary (CHO) Cell Line to a rFVIII Produced by a Baby Hamster Kidney (BHK) Cell Line (Kogenate FS).
Latest Information Update: 01 Jan 2015
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Bayer
Most Recent Events
- 09 Mar 2009 New trial record